Key Takeaways

Tirzepatide produced greater average weight loss than semaglutide in a 72-week clinical trial.
Dual-hormone targeting may explain the stronger weight-loss response seen with tirzepatide.
Both medications improved metabolic health markers.
Gastrointestinal side effects were common with both therapies.
Medication selection should depend on overall health goals, medical history, and treatment access.

For decades, obesity treatment centered on calorie restriction, exercise plans, and medications that often delivered limited long-term success. The arrival of GLP-1-based therapies has changed that landscape dramatically. Patients are now achieving levels of weight reduction that were once considered difficult without bariatric surgery.

Among the most closely watched medications are Zepbound and Wegovy. Both are designed to reduce appetite, improve satiety, and support sustained weight loss. But recent head-to-head clinical data suggest that tirzepatide may produce greater overall weight reduction than semaglutide in many adults living with obesity.

The difference appears to come down to biology. Although the two medications belong to the same broader class of obesity treatments, they do not work in exactly the same way. Understanding that distinction helps explain why weight-loss outcomes may differ between the two therapies.

Follow Our: Why Zepbound Users Lose More Weight Than Wegovy Users

Tirzepatide vs Semaglutide: Understanding the Core Difference

How These Medications Affect Appetite and Metabolism

Both tirzepatide and semaglutide influence hormones involved in digestion, hunger signaling, and feelings of fullness after eating. Patients taking these medications typically report reduced cravings, earlier satiety, and lower overall calorie intake.

Semaglutide, the active ingredient in Wegovy, works by targeting the GLP-1 receptor. GLP-1 is a hormone involved in appetite regulation and blood sugar control.

Tirzepatide, the active ingredient in Zepbound, targets both GLP-1 and another hormone pathway called GIP (glucose-dependent insulinotropic polypeptide).

This dual action is one of the most important scientific differences between the two medications.

Follow Our: Follow Our: Mounjaro vs. Zepbound: Same Drug, Different Missions in Diabetes and Weight Loss

Why Dual-Hormone Therapy May Produce Greater Weight Loss

Researchers believe tirzepatide’s additional effect on the GIP receptor may strengthen appetite suppression and metabolic regulation beyond what is typically seen with GLP-1 therapy alone.

In practical terms, both medications help patients eat less and feel fuller for longer periods. However, activating two hormonal pathways instead of one may create a stronger cumulative effect on body weight regulation.

That theory gained significant attention after a large head-to-head clinical trial directly compared tirzepatide with semaglutide.

What the Clinical Trial Revealed

A study published in the New England Journal of Medicine evaluated adults in the United States who had obesity or overweight with at least one weight-related health condition, excluding diabetes.

The trial followed 751 participants over 72 weeks.

Weight Loss Outcomes

Participants taking tirzepatide lost an average of:

About 50 pounds (22.8 kilograms)
Roughly 20% of their body weight

Participants taking semaglutide lost an average of:

About 33 pounds (15 kilograms)
Nearly 14% of their body weight

The difference between the two groups was clinically meaningful. Nearly one-third of participants using tirzepatide lost at least 25% of their body weight, compared with approximately 16% of participants using semaglutide.

The findings reinforced growing interest in dual-agonist therapies as a potentially more effective option for some patients with obesity.

Follow Our: Follow Our: Mounjaro vs. Wegovy: Weight Loss Comparison

Waist Circumference and Cardiometabolic Health

The trial also measured changes in waist circumference, an important marker because excess abdominal fat is strongly associated with cardiovascular and metabolic disease risk.

Participants using tirzepatide reduced waist circumference by approximately:

17.8 centimeters (about 7 inches)

Participants using semaglutide reduced waist circumference by approximately:

12.7 centimeters (about 5 inches)

As weight loss increased, researchers also observed improvements in several metabolic health markers, including:

Blood pressure
Blood sugar levels
Blood fat measurements

These changes suggest that the benefits of treatment may extend beyond body weight alone.

Side Effects Were Common With Both Medications

Although tirzepatide demonstrated greater average weight loss, the overall side-effect profile between the two medications was broadly similar.

Most adverse effects involved the gastrointestinal system and ranged from mild to moderate severity.

Commonly Reported Side Effects

Patients reported symptoms including:

Nausea
Vomiting
Diarrhea
Constipation
Abdominal discomfort
Heartburn
Fatigue
Headache
Dizziness
Hair loss
Injection-site reactions

More than three-quarters of participants in both treatment groups experienced at least one side effect during the trial.

Treatment Discontinuation Rates

About:

6% of tirzepatide users discontinued treatment because of side effects
8% of semaglutide users discontinued treatment because of side effects

Individual tolerance can vary considerably, which is one reason obesity specialists emphasize personalized treatment decisions.

Follow Our: Ozempic vs. Wegovy: A Clinician’s Guide to Semaglutide for Diabetes and Weight Management

Why Wegovy Still Plays an Important Role in Obesity Care

Greater weight loss does not automatically mean a medication is the best choice for every patient.

Wegovy has several important advantages supported by clinical evidence.

Cardiovascular Risk Reduction

Semaglutide has been shown to reduce the risk of serious cardiovascular events by 20% in adults with heart disease.

That benefit is particularly important because obesity and cardiovascular disease frequently overlap.

Approval for Younger Patients

Wegovy is approved for adults and adolescents age 12 and older, whereas Zepbound is currently approved only for adults.

Fatty Liver Disease Treatment

Wegovy also carries approval for a form of fatty liver disease, expanding its role beyond weight reduction alone.

Tirzepatide’s Expanding Clinical Applications

Tirzepatide has also shown benefits in obstructive sleep apnea, highlighting how obesity medications are increasingly being studied for broader metabolic and obesity-related conditions.

Research in this field continues to evolve rapidly. Investigators are evaluating long-term outcomes, additional therapeutic uses, and the role of these medications in different patient populations.

Cost and Access Remain Major Barriers

Despite the growing popularity of GLP-1-based medications, affordability and insurance coverage continue to limit access for many patients.

Both tirzepatide and semaglutide were recently removed from the U.S. FDA shortage list. Manufacturers have also introduced pricing programs designed to reduce monthly treatment costs.

Insurance coverage decisions may still shape prescribing patterns. CVS Health recently announced that Wegovy would become the preferred option on its standard formulary beginning July 1, while Zepbound would be excluded.

For many patients, real-world access may influence medication choice as much as clinical effectiveness.

Follow Our: Can You Lose Weight on Wegovy Without Diet or Exercise?

Obesity Treatment Is Becoming More Personalized

Obesity specialists increasingly emphasize that treatment decisions should be individualized rather than driven solely by maximum weight-loss percentages.

Some patients may prioritize:

Greater total weight loss
Cardiovascular protection
Lower side-effect burden
Coverage through insurance
Use in adolescents
Long-term tolerability

Response to obesity medications can differ substantially from one person to another. A therapy that produces exceptional results for one patient may not work as well for another.

The broader shift in obesity medicine is not simply about achieving lower numbers on a scale. It is about improving long-term metabolic health and reducing obesity-related disease risk.

Clinical Summary: Fact Boxes

Tirzepatide vs Semaglutide at a Glance

Tirzepatide (Zepbound)

Dual-agonist medication targeting GLP-1 and GIP
Average weight loss around 20% in clinical trial data
Greater average waist circumference reduction
Proven benefit in obstructive sleep apnea
Approved for adults 18 and older

Semaglutide (Wegovy)

GLP-1 receptor agonist
Average weight loss around 14% in the head-to-head study
Proven cardiovascular risk reduction benefit
Approved for adolescents and adults
Approved for a form of fatty liver disease

Medical Disclaimer

This article is intended for educational and informational purposes only and should not be interpreted as medical advice, diagnosis, or treatment. Weight-loss medications such as tirzepatide and semaglutide may not be appropriate for every individual and can carry significant risks and side effects. Always consult a licensed healthcare professional before starting, changing, or discontinuing any medication or weight-management treatment plan.

Tirzepatide vs Semaglutide: The Science Behind the Weight Loss Gap